$TAK

Furney Natalie Anne Marie sold $528K of TAK

Furney Natalie Anne Marie (Global General Counsel) sold 30,868 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $17.10 ($0.53M total) on 2026-08-10.

Original reporting
SEC EDGAR · Furney Natalie Anne Marie
Published Aug 13, 2026, 1:23 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TAK
Neutral
low confidence
Mentioned
$TAK
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TAKNeutralLow
01

Why it matters

The newest fact is the reported open-market sale by the Global General Counsel: 30,868 shares at $17.10 for about $527,842.80, with holdings after the sale of 204,298 shares and no pre-arranged 10b5-1 plan.

02

Market read

Traders may briefly reassess sentiment around insider behavior, but there is no fundamental catalyst in the text.

03

What to watch

The article does not state insider compensation needs, tax planning, or whether sales were part of broader personal liquidity actions; without that context, signal quality is low.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-12 after trade on 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for Takeda Pharmaceutical Co Ltd (TAK).

Company-level read

Ticker impact

$TAKNeutralLow confidence
Context

Takeda disclosed an officer open-market sale of 30,868 shares at $17.10 on 2026-08-10 via an SEC Form 4 filing.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven and typically fades.

Evidence & confidence

The filing provides transaction details only. Insider sales are common and the article includes no accompanying guidance, operational update, or regulatory/legal catalyst.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Absence of a 10b5-1 plan could be interpreted by some traders as less “mechanical,” potentially increasing short-term scrutiny.

Key entities

  • TAK

    Takeda Pharmaceutical Co Ltd, the subject of the Form 4 insider sale disclosure.

  • Furney Natalie Anne Marie

    Global General Counsel who sold 30,868 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TAKMedAI 9/10

Why Zasocitinib Outperformed Deucravacitinib in New Plaque Psoriasis Data

Zasocitinib, an investigational TYK2 inhibitor by Takeda, showed superior efficacy in treating plaque psoriasis compared to deucravacitinib in a phase 3 trial. 36.5% of patients achieved PASI 100 with zasocitinib vs. 13.9% with deucravacitinib. The drug's higher TYK2 selectivity and longer IL-23 blockade were cited as key factors. Zasocitinib is under review by the FDA and EMA.

$TAKHighAI 9/10

Oveporexton Improves Wakefulness and Cataplexy in Narcolepsy Type 1

Takeda's Oveporexton (Orzeyful) significantly improved wakefulness, daytime sleepiness, and cataplexy in narcolepsy type 1 patients over 12 weeks, according to two phase 3 trials. The FDA approved the drug in August 2026, positioning it as the first therapy addressing orexin deficiency. Adverse events included increased urinary frequency and transient insomnia. Trials showed mean sleep latency improvements of 14.3 to 19.8 minutes with Oveporexton vs. placebo.

$TAKMedAI 8/10

Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill

Takeda announced Phase 3 trial results showing zasocitinib (TAK-279) demonstrated superior efficacy in treating moderate-to-severe plaque psoriasis compared to deucravacitinib. Key data: 36.5% of patients achieved complete skin clearance (PASI 100) at week 16 vs. 13.9% for deucravacitinib. Zasocitinib also showed durable skin clearance and improvements in itch and quality of life. The drug is under regulatory review for psoriasis treatment.

$TAKMedAI 9/10

Takeda Pharmaceutical Company Limited: Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026

Takeda (TSE:4502/NYSE:TAK) will present data on its oncology pipeline at ESMO 2026, including Phase 3 results for arcotatug tavatecan in advanced gastric cancer and findings on TAK-928 for NSCLC. The company is expanding a global Phase 3 study for TAK-928.